Vitamin D analogues in insulin-dependent diabetes mellitus and other autoimmune diseases: A therapeutic perspective

Diabetes/Metabolism Reviews

Volumn 12, Issue 1, 1996, Pages 57-68

  Mauricio, Dídac ^a   Mandrup Poulsen, Thomas ^a   Nerup, Jørn ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CALCIPOTRIOL; CALCITRIOL; LEXACALCITOL; VITAMIN D DERIVATIVE;

AUTOIMMUNITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTRAPERITONEAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030002605     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199603)12:1<57::AID-DMR157>3.0.CO;2-L     Document Type: Review

References (87)

1. Rigby WFC: The inununobiology of vitamin D. Immunol Today 9: 54-58, 1988.
2. Walters MR: Newly identified actions of the vitamin D endocrine system. Endocr Rev 13: 719-764, 1992.
3. Bikle DD: Vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 13: 765-784, 1992.
4. 3. Kidney Int 38 (Suppl 29): S9-S16, 1990.
5. Manolagas SC, Yu XP, Girasole G, and Bellido T: Vitamin D and the hematolymphopoietic tissue: a 1994 update. Semin Nephrol 14: 129-143, 1994.
6. 3 prevents insulitis in NOD mice. Diabetes 41: 1491-1495, 1992.
7. 3. Diabetologia 37: 552-558, 1994.
8. 3 and the analogues MC903 and KH1060 on interleukin-lβ-induced inhibition of pancreatic islet β-cell function in vitro. Immunol Lett 41: 73-77, 1994.
9. Mathieu C: Immune intervention in animal models of type I diabetes: pathogenetical and therapeutical aspects. Doctoral thesis, Catholic University of Leuven, 1994.
10. Nerup J, Mandrup-Poulsen T, Helqvist S, Andersen HU, Pociot F, Reimers JI, Cuartero BG, Karlsen AE, Bjerre U, and Lorenzen T: On the pathogenesis of IDDM. Diabetologia 37 (Suppl. 2): S82-S89, 1994.
11. Gale E AM and Bingley PJ: Can we prevent IDDM? Diabetes Care 17:339-344, 1994.
12. Pociot F, Reimers J, and Andersen HU: Work-shop report: Nicotinamide - biological actions and therapeutical potential in diabetes prevention. IDIG Workshop, Copenhagen, December 4-5, 1992. Diabetologia 36: 574-576, 1993.
13. Keller RJ, Eisenbarth GS, and Jackson RA: Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 341: 927-928, 1993.
14. Fraser DR: Vitamin D. Lancet 345: 104-107, 1995.
15. Reichel H, Koeffler, HP, and Norman AW: The role of the vitamin D endocrine system in health and disease. N Engl J Med 320: 980-991, 1989.
16. Pols HAP, Birkenhäger JC, and van Leeuwen JPTM: Vitamin D analogues: from molecule to clinical application. Clin Endocrinol 40: 285-291, 1994.
17. Carson-Jurica MA, Schrader WT, and O'Malley BW: Steroid receptor family: structure and functions. Endocr Rev 11: 201-220, 1990.
18. MacDonald PN, Dowd DR, and Haussler MR: New insight into the structure and functions of the vitamin D receptor. Semin Nephrol 14: 101-118, 1994.
19. Morrison NA, Shine J, Fragonas JC, Verkest V, McMenemy ML, and Eisman JA:1,25 Dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science 246: 1158-1161, 1989.
20. Barsony J and Marx SJ: Rapid accumulation of cyclic GMP near activated vitamin D receptors. Proc Natl Acad Sci USA 88: 1436-1440, 1991.
21. Stern PH: The D vitamins and bone. Pharmacol Rev 32: 47-80, 1980.
22. Henry HL and Norman AW: Vitamin D: metabolism and biological actions. Annu Rev Nutr 4: 493-520, 1984.
23. 3 of transcription of preproparathyroid hormone gene. Endocrinology 119: 2864-2866, 1986.
24. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 80: 201-204, 1983.
25. Colston KW, Berger U, and Coombes RC: Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet i: 188-191, 1989.
26. Pols HAP, Birkenhäger JC, Foekens JA, and van Leeuwen JPTM: Vitamin D: a modulator of cell proliferation and differentiation. J Steroid Biochem Mol Biol 37: 873-876, 1990.
27. Binderup L: Immunological properties of vitamin D analogues and metabolites. Biochem Pharmacol 43: 1885-1892, 1992.
28. Brown AJ, Dusso A, and Slatopolsky E: Selective vitamin D analogs and their therapeutic applications. Semin Nephrol 14: 156-174, 1994.
29. 3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 42: 1569-1575, 1991.
30. Kragballe K, Gjertsen BT, dejoop D, Karlsmark T, van de Kerkhof PCM, Larkö, Nieboer C, Roed-Petersen J, Strand A, and Tikjøb G: Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 337: 193-196, 1991.
31. 3 receptors in human leukocytes. Science 221: 1181-1183, 1983.
32. Stroder J and Kasal P: Evaluation of phagocytosis in rickets. Acta Paediatr Scand 59: 288-292, 1970.
33. 3 on mouse peritoneal macrophage functions. J Immunol 143: 3686-3690, 1989.
34. 3 produced by cultured alveolar macrophages in sarcoidosis. J Clin Endocrinol Metab 60: 960-966, 1985.
35. 3 activates secretion of hydrogen peroxide by human monocytes. J Immunol 136: 1049-1053, 1986.
36. 3 maintains adherence of human irtonocytes and protects them from thermal injury. J Clin Invest 77: 1332-1339, 1986.
37. 3 by normal human macrophages. Biochem Biophys Res Commun 127: 596-603, 1985.
38. 3 metabolism by lipopolysaccharide-stimulated normal human macrophages. J Clin Endocrinol Metab 64: 1-9, 1987.
39. 3. Blood 76: 189-197, 1990.
40. 3. J Cell Biochem 48: 26-31, 1992.
41. Saggese G, Federico G, Balestri M, and Toniolo A: Calcitriol inhibits the PHA-induced production of IL-2 and IFN-T and the proliferation of human peripheral blood leukocytes while enhancing the surface expression of HLA class II molecules. J Endocrinol Invest 12: 329-335,1989.
42. 3. J Immunol 136: 2181-2186, 1986.
43. 3 downregulation of HLA-DR on human peripheral blood monocytes. Immunology 75: 349-354, 1992.
44. 3. Int J Immunopharmacol, 13: 525-530, 1991.
45. 2, interleukin-1, and tumor necrosis factor α. by human monocytes. Bone 13: 185-189, 1992.
46. 3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 57: 1308-1310, 1983.
47. 3 inhibits antigen-induced T cell activation. J Immunol 133: 1748-1754, 1984.
48. 3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 134: 3032-3035, 1985.
49. 3 receptor distribution and effects in subpopulations of normal human T lymphocytes. J Clin Endocrinol Metab 68: 774-779, 1989.
50. 3. Immunol Lett 28: 115-120, 1991.
51. Vanham G, Ceuppens JL, and Bouillon R: T lymphocytes and their CD4 subset are direct targets of the inhibitory effect of calcitriol. Cell Immunol 124: 320-333, 1989.
52. 3 enhances the generation of nonspecific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR. Cell Immunol 140: 400-409, 1992.
53. 3 on T lymphocyte subpopulations. Eur J Immunol 17: 563-566, 1987.
54. Manolagas SC, Provvedini DM, Murray EJ, Tsoukas CD, and Deftos LJ: The antiproliferative effect of calcitriol on human peripheral blood mononuclear cells. J Clin Endocrinol Metab 63: 394-400, 1986.
55. 3 on human peripheral blood lymphocyte immunoglobulin production. Mol Endocrinol 27: 95-100, 1990.
56. 3 mediated inhibition of B cell function in vitro. Immunopharmacology 21: 121-128, 1991.
57. 3 on in vitro immunoglobulin production in human B cells. J Immunol 136: 4427-4431, 1986.
58. 3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. J Immunol 136:2734-2739, 1986.
59. Tsoukas CD, Watry D, Escobar SS, Provvendini DM, Dinarello CA, Hustmyer FG, and Manolagas SC: Inhibition of interleukin-1 production by 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 69: 127-133, 1989.
60. 3 inhibits γ-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 84: 3385-3389, 1987.
61. 3. J Clin Invest 79: 1659-1664, 1987.
62. 3 inhibits the production of IL-12 by human monocytes and B cells. FASEB J 8: A745, 1994.
63. Rook GAW, Hernandez-Pando R, and Lightman SL: Hormones, peripherally activated prohormones and regulation of the Thl/Th2 balance. Immunol Today 15: 301-303, 1994.
64. 16-cholecalciferol. Transplantation 54: 762-763, 1992.
65. Veyron P, Pamphile R, Binderup L, and Touraine JL: Two novel vitamin D analogues, KH1060 and CB966, prolong skin allograft survival in mice. Transplant Immunol 1: 72-76, 1993.
66. 3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol 98: 311-322, 1986.
67. 3 analogues with potent effects on cell growth regulation and immune responses: structure activity studies. In Vitamin D: Gene Regulation, Structure Function Analysis and Clinical Application, Norman AW, Bouillon R, and Thornasset M (Eds). Walter de Gruyter, Berlin, 1991, pp 478-485.
68. 3: potent modulation of the hormonal effects by phorbol esters. Immunology 77: 520-526, 1992.
69. 3 modulation of TNF and IL-1-beta expression in human peripheral blood mononuclear cell lines. Transplantation 51: 498-503, 1991.
70. 3 and a novel vitamin D analogue MC903 are potent inhibitors of human interleukin 1 in vitro. Immunol Lett 17: 361-366, 1988.
71. 3 in U937 cells. Eur Cytokine Netw 4: 285-292, 1993.
72. 3 increases type I interleukin-1 receptor expression in a murine T cell line. J Cell Biochem 52: 159-170, 1993.
73. Latini S and Binderup L: KH1060 a new vitamin D analogue with potent effects on cell-mediated immune responses in vitro. In Vitamin D: Gene Regulation, Structure Function Analysis and Clinical Application, Norman AW, Bouillon R, and Thornasset M (Eds). Walter de Gruyter, Berlin, 1991, pp 516-517.
74. 3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 87: 1103-1107, 1991.
75. 3 on the induction of experimental autoimmune thyroiditis. Clin Immunol Immunopathol 54: 53-63, 1990.
76. 3. Clin Exp Immunol 94: 412-417, 1993.
77. 3 inhibits type II collagen-induced arthritis in rats. FEES Lett 337: 248-250, 1994.
78. Lillevang ST, Rosenkvist J, Andersen CB, Larsen S, Kemp E, and Kristensen T: Single and combined effects of the vitamin D analogue KH1060 and cyclosporin A on mercuric-chloride-induced autoimmune disease in the BN rat. Clin Exp Immunol 88: 301-306, 1992.
79. 28k in human and rat pancreas. Am J Physiol 267: E356-E360, 1994.
80. Gedik O and Akalin S: Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Dinbetologia 29: 142-145, 1986.
81. Kumar S, Davies M, Zakaria Y, Mawer EB, Gordon C, Olukoga AO, and Boulton AJM: Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J 70: 440-443, 1994.
82. Chertow BS, Sivitz WI, Baranetsky G, Clark SA, Waite A, and Deluca HF: Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology 113: 1511-1518, 1983.
83. 3 on the pancreatic secretion of insulin and somatostatin. Acta Endocrinol 105: 528-533, 1984.
84. 3 enhances the effect of refeeding on steady state preproinsulin messenger ribonucleic acid levels in rats. Endocrinology 126: 2041-2045, 1990.
85. Norman AW: The vitamin D endocrine system: identification of another piece of the puzzle. Endocrinology 134: 1601A-1601C, 1994.
86. 3 and pancreatic β-cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology 134: 1602-1610, 1994.
87. 3 against the development of diabetes induced by multiple low-dose streptozotocin injection in CD-1 mice. Metabolism 41: 631-635, 1992.